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Abstract
Purpose. Stenotrophomonas maltophilia is a multidrug-resistant opportunistic pathogen causing an increasing number of
nosocomial infections. Our aim was to evaluate the risk factors and mechanisms associated with trimethoprim–
sulfamethoxazole (SXT) resistance in S. maltophilia infections in Mexico.
Methodology. Clinical isolates and patients’ demographic and clinical data were collected from February 2007 to August
2015 in two tertiary-care hospitals in Mexico. Antimicrobial susceptibility and analysis of sul and SmeABC and SmeDEF
efflux pump overexpression were performed in all isolates.
Results/Key findings. In the 9-year period, 196 patients infected with S. maltophilia were identified. Most patients were male,
and the mean age was 46.2 years. The mean Charlson score was 1.42, and the most frequent comorbidities were arterial
hypertension (26.7%), type 2 diabetes (21.2%) and cerebral infarction (11.6%). High drug resistance to meropenem (93.4%),
gentamicin (55.1%), ceftazidime (52.3%), cefotaxime (51.5%), amikacin (42.3%) and cefepime (32.1%), and lower resistance
to ciprofloxacin (26.0%), SXT (25.0%), chloramphenicol (14.3%) and levofloxacin (2.6%) were detected. SXT resistance was
not associated with the sul genes. SmeABC overexpression was associated with gentamicin (P=0.001) and levofloxacin
resistance (P=0.041), whereas SmeDEF overexpression was associated with ceftazidime resistance (P=0.003). Prolonged
hospitalization (15 days) was an independent risk factor for SXT-resistant S. maltophilia infections (OR=3.05; 95%CI=1.12–
8.86; P=0.029).
Conclusion. Given the high SXT resistance rate, SXT is not an effective first-line therapy for our patients; instead,
levofloxacin could be used as an appropriate therapeutic option against S. maltophilia infections.
INTRODUCTION
Stenotrophomonas maltophilia is a non-fermenting Gram-
negative bacillus that has emerged as an opportunistic drug-
resistant pathogen that is responsible for an increasing
number of nosocomial infections and particularly affects
immunocompromised patients, with significant morbidity
and mortality [1–3]. The risk factors for S. maltophilia
infections are a severely compromised health status, malig-
nancies, cystic fibrosis, indwelling devices such as intravas-
cular catheters and ventilation tubes, exposure to broad-
spectrum antimicrobials and prolonged hospitalization [2,
4]. However, the impact of acquiring trimethoprim–sulfa-
methoxazole (SXT)-resistant S. maltophilia infections has
been poorly studied.
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S. maltophilia strains tend to have high rates of intrinsic or
acquired antimicrobial resistance that reduce our therapeu-
tic options [5]. SXT is a common first-line antimicrobial
treatment because resistance rates used to be very low (less
than 10%) [5, 6]. In recent years, however, the SXT resis-
tance rate has been gradually increasing, and it has been
reported to be over 38.7% [7].
Several molecular mechanisms have been shown to contrib-
ute to the antimicrobial resistance of S. maltophilia, e.g. the
activity of multidrug efflux pumps, such as SmeABC and
SmeDEF [8–12], and the presence of drug-resistance genes,
such as the sul genes [8, 13].
The aim of this study was to evaluate the risk factors and
molecular mechanisms associated with SXT resistance in S.
maltophilia infections.
METHODS
Study design
The study was conducted at two tertiary-care Mexican hospi-
tals: the Hospital Universitario Dr Jose Eleuterio Gonzalez in
Nuevo Leon and the Hospital Civil de Guadalajara in Jalisco.
Only patients with confirmed S. maltophilia infection were
included [14]. Data from the first episode were included if
patients had multiple infections with S. maltophilia. Demo-
graphic and clinical data were retrieved from patient charts.
The Charlson comorbidity index was used as a surrogate mea-
sure for comorbidities [15]. Patients whose medical records
were unavailable were not included in the statistical analysis.
Patients younger than 18 years old were excluded.
Clinical isolates
Clinical isolates of S. maltophilia were collected from Febru-
ary 2007 to August 2015. S. maltophilia isolates were
identified using Sensititre panels (TREK Diagnostic Sys-
tems, Cleveland, OH, USA) according to the manufacturer’s
instructions, by PCR amplification of a 134 bp fragment of
the 16S rRNA gene [16] and by MALDI-TOF mass spec-
trometry (Bruker Daltonics, Bremen, Germany). S. malto-
philia ATCC 13637 was used as a wild-type control strain.
All of the isolates were stored at  70

C until use.
Antimicrobial susceptibility
The minimum inhibitory concentration (MIC) was deter-
mined by the broth microdilution method. Panels were
obtained from Sensititre (TREK Diagnostic Systems Inc.)
and used according to the manufacturer’s instructions. The
antimicrobial agents for susceptibility testing included ami-
kacin, cefepime, cefotaxime, ceftazidime, chloramphenicol,
ciprofloxacin, gentamicin, levofloxacin, meropenem and
SXT. The results were interpreted according to the Clinical
and Laboratory Standards Institute (CLSI) criteria [17]. For
antimicrobial agents without specific CLSI criteria for S.
maltophilia, criteria that were relevant for non-Enterobac-
teriaceae were used.
Antimicrobial resistance mechanisms
Sme efflux pump expression
Total RNA was isolated using the RNeasy mini kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
instructions. Expression of the Sme efflux systems, SmeABC
and SmeDEF, was assessed by real-time PCR using previ-
ously described specific primers (Table 1). rDNA was used
as the endogenous control gene [9]. Real-time PCR
reactions were performed on the Cepheid SmartCycler II
real-time PCR system (Cepheid, Sunnyvale, CA, USA).
Amplification mixtures were prepared using the SensiFast
SYBR No-ROX One-Step kit (Bioline, Taunton, MA, USA)
and contained 2 SensiFast SYBR No-ROX One-Step mix,
Table 1. Primer sequences used in this study
Gene Designation Sequence (5¢ to 3¢) Annealing temperature Product (bp) Reference
Sme efflux pump expression
smeABC Forward ACCGCCCAGCTTTCATACAG 60 69 [9]
Reverse GACATGGCCTACCAGGAACAG [9]
smeDEF Forward TCGTCCAGGCTGACATTCAA 60 62 [9]
Reverse AACGCGGATCGTGATATCG [9]
rDNA Forward TGACACTGAGGCACGAAAGC 60 30 [9]
Reverse CATCGTTTAGGGCGTGGACTA [9]
SXT resistance mechanisms
sul1 Forward ATGGTGACGGTGTTCGGCATTCTGA 50 840 [13]
Reverse CTAGGCATGATCTAACCCTCGGTCT [13]
sul2 Forward GAATAAATCGCTCATCATTTTCGG 50 810 [13]
Reverse CGAATTCTTGCGGTTTCTTTCAGC [13]
sul3 Forward GAGCAAGATTTTTGGAATCG 51 752 [24]
Reverse CATCTGCAGCTAACCTAGGGCTTTGGA [24]
ISCR Forward GCGAGTCAATCGCCCACT 50 [13]
Reverse CGACTCTGTGATGGATCGAA [13]
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1 reverse transcriptase, 1 RiboSafe RNase inhibitor,
400 nM of each primer and 10 ng µl 1 of total RNA. After a
5min retrotranscription step at 45

C and a 2min activation
step at 95

C, the PCR process consisted of 40 cycles of
denaturation at 95

C for 15 s, annealing at 60

C for 30 s
and extension at 72

C for 30 s. The expression levels of S.
maltophilia ATCC 13637 were used to construct the stan-
dard curves of smeABC, smeDEF and rDNA, which were
used as calibrators to normalize the relative expression lev-
els in clinical isolates. A formula including the Ct values of
Sme and the endogenous gene in both the samples and cali-
brators was used to express n-fold differences in the expres-
sion of smeABC or smeDEF genes, in which values of n<1
were considered to indicate overexpression of the Sme efflux
system [10].
SXT resistance mechanisms
All of the isolates were screened for the presence of sul1,
sul2, and sul3 genes and insertion element common region
(ISCR) elements using previously described primers and
PCR conditions (Table 1). Briefly, the reaction mixtures
contained 1 PCR buffer, 2mM MgCl2, 0.2mM
concentration of each dNTP, 200 nM of each primer, 1 U of
AmpliTaq polymerase (Bioline, Taunton, MA, USA) and
200 ng of DNA extracted by thermal lysis. PCR was initiated
by denaturation for 5min at 95

C, followed by 30 cycles of
1min denaturation at 95

C, 1min annealing at 50

C and
1min extension at 68

C, with a final 5min extension at
72

C.
Statistical analysis
Student’s t-test and one-way ANOVA were used to verify
significant differences in efflux pump expression between
susceptible and resistant isolates. Categorical variables were
compared using Fisher’s exact test or Chi-squared
distribution; continuous variables were analysed using Stu-
dent’s t-test. A multivariate analysis was performed using
the logistic regression method to identify independent risk
factors associated with SXT-resistant S. maltophilia infec-
tions. P<0.05 was considered to be statistically significant.
Odds ratios (ORs) and corresponding 95% confidence
intervals (CIs) were computed using SPSS statistics software
version 20.0 (IMB Corporation, Somers, NY, USA).
RESULTS
Clinical isolates
In total, 196 isolates from 196 patients were collected during
the 9-year study period: 169 (86.2 %) isolates were from
Nuevo Leon and 27 (13.8%) were from Jalisco. Most of the
isolates were from the respiratory tract (63.3 %, n=124) fol-
lowed by blood (17.3 %, n=34), wounds (5.1%, n=10), urine
(2.0%, n=4), abscesses (1.5%, n=3), pleural fluid
(1.5%, n=3), bile (0.5%, n=1), cerebrospinal fluid
(0.5%, n=1) and unidentified origin (8.2 %, n=16).
Patient characteristics
One hundred and forty-six patients had a complete medical
chart and were included in the clinical analysis (Table 2).
The majority of patients were male (65.1 %, n=95) and the
age range was 18–87 years, with a mean of 46.2 years. The
most frequent comorbidities were arterial hypertension
(26.7%, n=39), type 2 diabetes (21.2%, n=31) and cerebral
infarction (11.6%, n=17). The Charlson score mean was
1.42±1.69. Invasive procedures were common: 66.4%
(n=97) had a urinary catheter, 64.4% (n=94) had a central
catheter (64.4%, n=94) and 53.4% (n=78) received mechan-
ical ventilation. Most patients (n=135; 92.5%) were on
antibiotics during sample recollection. The most prescribed
antibiotics were carbapenems (92.5 %, n=71), vancomycin
(38.4%, n=56) and third-generation cephalosporins (25.3%,
n=37) (data not shown). Almost two-thirds of the patients
(66.4%, n=97) were hospitalized for more than 15 days,
more than half (57.5%, n=84) were admitted to the inten-
sive care unit (ICU) and 66 patients (45.2%) died.
Antimicrobial susceptibility
Table 3 summarizes the susceptibility data. The resistance
rates were high for meropenem (93.4%), gentamicin
(55.1%), ceftazidime (52.3%), cefotaxime (51.5%), amika-
cin (42.3%) and cefepime (32.1%). Lower resistance rates
were found for ciprofloxacin (26.0%), SXT (25.0%), chlor-
amphenicol (14.3%) and levofloxacin (2.6%). The
comparison of resistant rates per year is shown in Fig. 1,
where the resistance rates to SXT showed a decrease
through the years.
Antimicrobial resistance mechanisms
Expression of Sme efflux pumps was analysed in isolates resis-
tant to either quinolones, chloramphenicol, or SXT. Among
the 91 selected/included isolates, 68 (74.7%) overexpressed the
SmeABC efflux pump, and 60 (65.9%) overexpressed the Sme-
DEF efflux pump. Overexpression of the SmeABC efflux
pump was significantly associated with resistance to gentami-
cin (P=0.001) and levofloxacin (P=0.041) whereas overexpres-
sion of the SmeDEF efflux pump was associated with
ceftazidime resistance (P=0.003) (Table 3).
SXT resistance was not associated with the presence of
either the sul genes (sul1: 4.2%, n=8; sul2: 0.5%, n=1; sul3:
0.0%, n=0) or the ISCR element (0.0 %, n=0).
Risk factors for SXT-resistant strain infection
Patients with gastrostomy/jejunostomy (OR=2.58; 95%
CI=1.11–6.02; P=0.037), tracheostomy (OR=2.39; 95%
CI=1.11–5.17; P=0.039), length of stay (15 days)
(OR=2.64; 95% CI=1.11–6.29; P=0.032) and lumbar punc-
ture (OR=3.41; 95% CI=1.21–9.58; P=0.022) had a higher
risk of acquiring a SXT-resistant S. maltophilia infection
(Table 2). An independent risk factor for acquiring SXT-
resistant S. maltophilia infection was length of stay (15
days) (OR=3.05; 95% CI=1.12–8.86; P=0.029) (Table 1).
Risk factors for general mortality in S. maltophilia
infection
In patients infected with S. maltophilia, 30-day mortality
was more frequent in patients with arterial hypertension
(OR=2.14; 95%CI=1.02–4.51; P=0.044), type 2 diabetes
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Table 2. Demographic and clinical characteristics of patients with Stenotrophomonas maltophilia infections
Patients infected with SXT-susceptible and SXT-resistant S. maltophilia isolates were compared using univariate and multivariate analysis.
Characteristic* No. (% of patients or range) SXT-resistant versus susceptible isolates General mortality
Univariate analysis Multivariate analysis Univariate analysis
Total SXT Odds
ratio (95%CI)
P Odds
ratio (95%CI)
P Odds
ratio (95%CI)
P
Resistant Susceptible
No. of patients 146 (100) 41 (28.1) 105 (71.9)
Mean age ±SD 46.2
±16.32
43.9±7.3 47.1±15.9 0.465
Male 95 (65.1) 26 (27.4) 69 (72.6) 1.10 (0.52–2.35) 0.305
Comorbidity
Arterial hypertension 39 (26.7) 11 (28.2) 28 (71.8) 1.01 (0.45–2.28) 1.000 2.14 (1.02–4.51) 0.044
Type 2 diabetes 37 (25.3) 6 (16.2) 31 (83.8) 0.41 (0.16–1.07) 0.089 2.73 (1.20–6.22) 0.015
Acute ischemic or haemorrhagic
stroke
17 (11.6) 5 (29.4) 12 (70.6) 1.08 (0.35–3.27) 1.000
Chronic kidney disease 15 (10.3) 3 (20.0) 12 (80.0) 0.61 (0.16–2.29) 0.558
Acute myocardial infarction 14 (9.6) 2 (14.3) 12 (85.7) 0.40 (0.09–1.86) 0.350 3.39 (1.01–11.38) 0.038
Acute kidney disease 13 (8.9) 4 (30.8) 9 (69.2) 1.15 (0.34–3.97) 0.758
Heart failure 10 (6.8) 2 (20.0) 8 (80.0) 0.62 (0.13–3.06) 0.726
Leukaemia 7 (4.8) 2 (28.6) 5 (71.4) 1.03 (0.19–5.51) 1.000 7.90 (0.93–67.38) 0.027
COPD 4 (2.7) 0 (0.0) 4 (100.0) 0.71 (0.64–0.79) 0.577
Peripheral artery disease 2 (1.4) 0 (0.0) 2 (100.0) 0.72 (0.65–0.79) 1.000
Connective tissue disease 1 (0.7) 0 (0.0) 1 (100.0) 0.71 (0.65–0.79) 1.000
Charlson score ± SD 1.42±1.69 0.98
±1.19
1.60±1.82 0.044 0.002
Invasive procedures
Urinary catheter 97 (66.4) 29 (29.9) 68 (70.1) 1.32 (0.60–2.87) 0.562 3.87 (1.80–8.32) 0.001
CVC 94 (64.4) 28 (29.8) 66 (70.2) 1.27 (0.59–2.74) 0.570 5.26 (2.41–11.49) 0.001
Mechanical ventilation 78 (53.4) 23 (29.5) 55 (70.5) 1.16 (0.56–2.40) 0.716 3.91 (1.95–7.85) 0.001
Surgery in past 90 days 17 (11.6) 7 (41.2) 10 (58.8) 1.86 (0.66–5.21) 0.263
Tracheostomy 41 (28.1) 17 (41.5) 24 (58.5) 2.39 (1.11–5.17) 0.039
Gastrostomy/jejunostomy 29 (19.9) 13 (44.8) 16 (55.2) 2.58 (1.11–6.02) 0.037
Hemodialysis/peritoneal dialysis 28 (19.2) 6 (21.4) 22 (78.6) 0.65 (0.24–1.73) 0.486 4.87 (1.92–12.37) 0.001
Arterial line 26 (17.8) 7 (26.9) 19 (73.1) 0.93 (0.36–2.42) 1.000
Lumbar puncture 17 (11.6) 9 (52.9) 8 (47.1) 3.41 (1.21–9.58) 0.022
Cardiac arrest 17 (11.6) 5 (29.4) 12 (70.6) 1.08 (0.35–3.27) 1.000 4.66 (1.44–15.08) 0.008
Pleural catheter 11 (7.5) 2 (18.2) 9 (81.8) 0.55 (0.11–2.65) 0.728
Administered drugs
Antibiotics during S. maltophilia
isolation
135 (92.5) 35 (25.9) 100 (74.1) 0.29 (0.08–1.02) 0.074
Antibiotics prior to S. maltophilia
isolation
38 (26.0) 10 (26.3) 28 (73.7) 0.89 (0.39–2.04) 0.837
Vancomycin 55 (37.7) 19 (34.5) 36 (64.5) 1.65 (0.78–3.46) 0.088 2.48 (1.25–4.91) 0.009
SXT 10 (6.8) 3 (30.0) 7 (70.0) 1.10 (0.22–4.44) 0.444 4.63 (0.93–23.09) 0.043
Antifungals 26 (17.8) 5 (19.2) 21 (80.8) 0.56 (0.19–1.59) 0.340 3.19 (1.33–7.65) 0.007
Corticosteroids 28 (19.2) 5 (17.9) 23 (82.1) 0.50 (0.17–1.41) 0.243 2.63 (1.12–6.18) 0.024
Vasopressors 26 (17.8) 5 (19.2) 21 (80.8) 0.56 (0.19–1.59) 0.340 9.50 (3.07–29.36) 0.001
Hospital stay
LOS (15 days) 97 (66.4) 33 (34.0) 64 (55.7) 2.64 (1.11–6.29) 0.032 3.05 (1.12–8.86) 0.029 2.51 (1.22–5.20) 0.012
ICU admission 84 (57.5) 27 (18.5) 57 (67.9) 1.62 (0.77–3.44) 0.264 4.23 (2.07–8.66) 0.001
Previous hospitalization 30 (20.5) 11 (36.7) 19 (63.3) 1.66 (0.71–3.89) 0.260
Outcome
Overall mortality 66 (45.2) 20 (30.3) 46 (69.7) 1.22 (0.59–2.52) 0.712
*COPD, chronic obstructive pulmonary disease; CVC, central venous catheter; ICU, intensive care unit; LOS, length of stay; SD, standard deviation;
SXT, trimethoprim–sulfamethoxazole.
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(OR=2.73; 95%CI=1.20–6.22; P=0.015), acute myocardial
infarction (OR=3.39; 95%CI=1.01–11.38; P=0.038), leukae-
mia (OR=7.90; 95%CI=0.93–67.38; P=0.027), urinary cath-
eter (OR=3.87; 95%CI=1.80–8.32; P0.001), central
venous catheter (OR=5.26; 95%CI=2.41–11.49; P0.001),
mechanical ventilation (OR=3.91; 95%CI=1.95–7.85;
P0.001), hemodialysis/peritoneal dialysis (OR=4.87;
95%CI=1.92–12.37; P0.001), cardiac arrest (OR=4.66;
95%CI=1.44–15.08; P=0.008), length of stay 15 days
(OR=2.51; 95%CI=1.22–5.20; P=0.012) and ICU admission
(OR=4.23; 95%CI=2.07–8.66; P0.001).
The use of corticosteroids (P=0.024), vasopressors
(P0.001), antifungals (P=0.007), vancomycin (P=0.009)
and SXT (P=0.043) were risk factors for 30 day mortality in
patients infected with S. maltophilia.
DISCUSSION
Clinical and microbiological data from patients infected
with S. maltophilia strains from two Mexican tertiary-care
hospitals were compared. S. maltophilia mainly affected
patients with respiratory infections who had been admitted
Table 3. Antimicrobial susceptibility and its correlation with the expression of smeABC and smeDEF in S. maltophilia isolates
Antimicrobial agent* MIC (µg/mL)† No. (%) of isolates‡ Sme efflux pumps overexpression
Mean MIC (SD)§
Range 50% 90% R I S smeABC (+)
n=68, 74.7%
smeABC ( )
n=23, 25.3%
P value smeDEF (+)
n=60, 65.9%
smeDEF ( )
n=31, 34.1%
P value
Amikacin 8 ->32 32 >32 83 (42.3) 59 (30.1) 54 (27.6) 41.8 (21.7) 43.4 (21.1) 0.419 40.5 (22.1) 45.6 (20.1) 0.102
Cefepime 2 ->16 16 >16 63 (32.1) 54 (27.6) 79 (40.3) 19.7 (10.2) 19.9 (10.5) 0.924 20.9 (10.2) 17.5 (10.1) 0.187
Cefotaxime 8 ->32 >32 >32 130 (66.3) 53 (27.0) 13 (6.6) 51.4 (20.4) 49.8 (21.0) 0.761 51.8 (20.2) 49.3 (21.1) 0.486
Ceftazidime 2 ->16 16 >16 101 (51.5) 23 (11.7) 72 (36.7) 22.7 (11.1) 24.4 (11.7) 0.870 24.5 (10.5) 20.4 (12.2) 0.003
Chloramphenicol 4 ->16 16 >16 28 (14.3) 87 (44.4) 81 (41.3) 17.0 (10.0) 20.8 (10.6) 0.201 17.5 (10.3) 18.8 (10.1) 0.877
Ciprofloxacin 0.5 ->2 2 >2 51 (26.0) 83 (42.3) 62 (31.6) 2.8 (1.2) 2.9 (1.3) 0.757 2.8 (1.4) 3.0 (1.3) 0.918
Gentamicin 0.5 ->32 >8 >8 108 (55.1) 32 (16.3) 56 (28.6) 12.5 (10.7) 19.7 (21.9) 0.001 14.3 (14.5) 14.5 (14.8) 0.863
Levofloxacin <0.5 ->4 2 2 5 (2.6) 5 (2.6) 186 (94.8) 2.2 (1.4) 2.7 (2.0) 0.041 2.3 (1.4) 2.4 (1.8) 0.350
Meropenem 2 ->32 >8 >32 183 (93.4) 5 (2.6) 8 (4.0) 19.1 (12.8) 16.0 (11.3) 0.358 18.8 (12.3) 17.3 (13.1) 1.000
SXT 0.5 -16 2 >2 49 (25.0) 0 (0.0) 147 (75.0) 2.8 (1.1) 4.3 (6.1) 0.060 2.9 (1.1) 3.8 (5.3) 0.178
*SXT, trimethoprim–sulfamethoxazole.
†MIC, minimum inhibitory concentration.
‡R, resistant; I, Intermediate; S, susceptible.
§SD, standard deviation; (+), positive for Sme efflux pump overexpression; ( ), negative for Sme efflux pump overexpression.
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Fig. 1. Comparison of resistance rates of S. maltophilia isolates per year. The percentage of isolates resistant to several antimicrobials
per year from 2012 to 2015 is shown. The data from the years 2007 to 2011 are not shown because the number of isolates per year
is too low (3) and they are not considered to be significant. AMK, amikacin; FEP, cefepime, CAZ, ceftazidime; CHL, chloramphenicol;
CIP, ciprofloxacin; GEN, gentamicin; LVX, levofloxacin; MEM, meropenem; and SXT, trimethoprim–sulfamethoxazole.
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to the ICU and subjected to multiple invasive procedures.
The overall mortality rate of patients with S. maltophilia
infection was 45.2%. Patients in the ICU, or under antibac-
terial therapy, or with arterial hypertension, type 2 diabetes,
acute myocardial infarction, leukaemia, intravascular cathe-
ters or ventilation tubes, or experiencing a prolonged stay in
hospital, were more likely to die.
According to the data shown above, S. maltophilia mainly
affects patients requiring hospitalization in the ICU and
with multiple invasive procedures. Attributable mortality
could not be clearly defined, however; the infection may
have worsened the clinical situation of patients and contrib-
uted to the high overall 30day mortality rate detected in this
study.
In our patients, a prolonged length of stay (15 days) was
an independent risk factor for infections with SXT-resistant
strains. A previous study that included patients with bacter-
emia by SXT-susceptible and SXT-resistant S. maltophilia
showed that mortality rates do not differ between the two
study groups, but patients with SXT-resistant isolates expe-
rienced prolonged hospitalization after the onset of bacter-
emia [18]. According to this study and our results, length of
stay seems to be the most important risk factor for infection
with SXT-resistant strains.
The usage of antibiotics may have favoured the selection of
drug-resistant S. maltophilia strains, and a prolonged length
of stay may have favoured the dissemination of these drug-
resistant strains within the hospital.
It is important to highlight the high resistance rate to carba-
penems, aminoglycosides and third-generation cephalo-
sporins, because these drugs are used as empirical therapies
in most common nosocomial infections. S. maltophilia is
intrinsically resistant to several of these groups of antibiot-
ics, including cephalosporins, carbapenems, macrolides and
aminoglycosides [5], and consequently treatment of S. mal-
tophilia infections with these antimicrobial groups is not
adequate. The use of these agents may have favoured the
colonization or infection with S. maltophilia. Indeed, the use
of carbapenems and cephalosporins has been described as a
risk factor for the development of S. maltophilia bacteremia
[19]. These findings underline the importance of
monitoring the incidence and the drug susceptibility of S.
maltophilia and underscore the importance of the de-escala-
tion of drugs used in empirical treatment after the causative
agent is defined.
SXT is regarded as a first-line drug for the treatment of S.
maltophilia infections, because SXT resistance rates used to
be less than 10% in multiple populations [5, 6, 8]. However,
SXT resistance rates vary geographically and have been
gradually increasing in recent years, reaching values of as
high as 32.8% in our hospitals in 2014 [20], and reaching
38.7% in Asian countries [7, 8]. Our follow-up study for
9 years of surveillance data showed a 25% resistance rate for
SXT, with a slight decrease per year. It seems that SXT is no
longer the best option to combat S. maltophilia infections in
several populations. For our population, levofloxacin and
chloramphenicol were the most active agents against S. mal-
tophilia and could be used as appropriate therapeutic
options, with special emphasis of levofloxacin against S.
maltophilia in respiratory infections [21].
Several mechanisms for antimicrobial drug resistance have
been reported worldwide in isolates of S. maltophilia [8],
including the expression of efflux pumps. Overexpression of
the SmeABC pump has been associated with resistance to
aminoglycosides [8, 10, 22] and fluoroquinolones [8–10]. In
our study, we confirmed the association of the overexpres-
sion of SmeABC with increased resistance to gentamicin
and levofloxacin (Table 4). Furthermore, the overexpression
of SmeDEF has been reported to be involved in resistance to
quinolones [8, 10, 11, 22], tetracyclines [8, 22], macrolides
[8], chloramphenicol [8, 11] and SXT [8, 12, 23]. Interest-
ingly, our results showed that the overexpression of Sme-
DEF was associated with increased resistance to ceftazidime
(Table 4).
The influence of Sme efflux pumps on the antimicrobial
resistance patterns of clinical isolates of S. maltophilia has
mainly been reported in Asian countries, such as Taiwan
[10, 23] and Korea [9, 22]. Our results represent the first
analysis of Sme efflux pump expression and the antimicro-
bial resistance patterns of clinical isolates of S. maltophilia
in Mexico. None of the Sme efflux pumps we analysed were
Table 4. Antimicrobial resistance and sme efflux pump overexpression in several studies
Country n Overexpression % Correlation of antimicrobial resistance and sme efflux pumps overexpression Reference
SmeABC SmeDEF SmeABC SmeDEF
Taiwan 93 59 31 CB, CFP, CIP, GEN, TET MER, CIP [10]
Taiwan 70 41 63 CAZ, FEP, TIM, TZP, MER, ATM, GEN, CIP, LEV, SXT [23]
Korea 33 64 58 CIP, LVX [9]
Korea 102 70–77 59–61 AMK AMK, LVX, MIN, MXF, TGC [22]
Mexico 91 75 66 GEN, LVX CAZ This study
AMK, amikacin; ATM, aztreonam; FEP, cefepime; CAZ, ceftazidime; CB, carbenicillin; CFP, cefoperazone; CIP, ciprofloxacin; GEN, gentamicin; LVX, levo-
floxacin; MEM, meropenem; MIN, minocycline; MXF, moxifloxacin; TET, tetracycline; TGC, tigecycline; TIM, ticarcillin/clavulanic acid; TZP, piperacillin/
tazobactam and SXT, trimethoprim–sulfamethoxazole.
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involved in SXT resistance. SXT resistance has been associ-
ated with the presence of class 1 integrons and ISCR linked
to the sul genes [13]. However, in our strain population,
SXT resistance was not associated with the presence of the
sul genes, suggesting that other underlying mechanisms are
involved.
Our study had several limitations. First, our study had an
ambispective design, so selection and observational bias
may have occurred. Second, not all isolate or patient data
were available. Third, the clonal relationship was not ana-
lysed for S. maltophilia isolates. Previously, we reported
high genetic diversity among clinical S. maltophilia isolates
from Mexico [20], which suggested independent acquisition
rather than cross-transmission. However, the impact of
patient-to-patient transmission in the present study cannot
be excluded. Finally, other potentially active agents against
S. maltophilia, such as ticarcillin/clavulanic acid and mino-
cycline, were not tested in our hospital, and assessments of
their clinical effects are unavailable.
In conclusion, this study was the first to evaluate the risk
factors associated with SXT-resistant S. maltophilia infec-
tions in Mexico. Prolonged length of stay was an indepen-
dent risk factor for SXT-resistant S. maltophilia infections.
Infection with SXT-resistant S. maltophilia did not increase
mortality, but it did lead to a prolonged hospital stay. SXT
resistance in S. maltophilia was not associated with either
SmeABC or SmeDEF pumps, or with sul genes or the ISCR
element. As S. maltophilia isolates from our population had
a high resistance rate to SXT, it should no longer be the
first-line therapy. Instead, levofloxacin could be used as an
appropriate therapeutic option against S. maltophilia
infections.
Funding information
The authors received no specific grant from any funding agency.
Acknowledgements
The authors thank María de la Luz Acevedo Duarte for assistance in
the laboratory.
Conflicts of interest
The authors declare that there are no conflicts of interest.
Ethical statement
This study was approved by the ethics committees of both the Hospital
Universitario ‘Dr Jose Eleuterio Gonzalez’, Universidad Autónoma de
Nuevo León (Approval GA15-005) and the Hospital Civil de Guadalajara
and Instituto de Patología Infecciosa y Experimental Dr Francisco Ruíz
Sanchez (approval 011/14), which waived the need for patients’
informed consent.
References
1. Senol E, Desjardin J, Stark PC, Barefoot L, Snydman DR. Attribut-
able mortality of Stenotrophomonas maltophilia bacteremia. Clin
Infect Dis 2002;34:1653–1656.
2. Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI,
Kapaskelis AM et al. Attributable mortality of Stenotrophomonas
maltophilia infections: a systematic review of the literature. Future
Microbiol 2009;4:1103–1109.
3. Denton M, Kerr KG. Microbiological and clinical aspects of infec-
tion associated with Stenotrophomonas maltophilia. Clin Microbiol
Rev 1998;11:57–80.
4. Nseir S, di Pompeo C, Brisson H, Dewavrin F, Tissier S et al.
Intensive care unit-acquired Stenotrophomonas maltophilia: inci-
dence, risk factors, and outcome. Crit Care 2006;10:R143.
5. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomo-
nas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007;26:
229–237.
6. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities
of a worldwide collection of Stenotrophomonas maltophilia iso-
lates tested against tigecycline and agents commonly used for
S. maltophilia infections. Antimicrob Agents Chemother 2010;54:
2735–2737.
7. Hu LF, Chen GS, Kong QX, Gao LP, Chen X et al. Increase in the
prevalence of resistance determinants to Trimethoprim/Sulfa-
methoxazole in clinical Stenotrophomonas maltophilia Isolates in
China. PLoS One 2016;11:e0157693.
8. Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections
caused by Stenotrophomonas maltophilia with particular attention
to resistance mechanisms and therapeutic options. Front Microbiol
2015;6:893.
9. Cho HH, Sung JY, Kwon KC, Koo SH. Expression of Sme efflux
pumps and multilocus sequence typing in clinical isolates of Sten-
otrophomonas maltophilia. Ann Lab Med 2012;32:38–43.
10. Chang LL, Chen HF, Chang CY, Lee TM, Wu WJ. Contribution of
integrons, and SmeABC and SmeDEF efflux pumps to multidrug
resistance in clinical isolates of Stenotrophomonas maltophilia. J
Antimicrob Chemother 2004;53:518–521.
11. Alonso A, Martínez JL. Cloning and characterization of SmeDEF, a
novel multidrug efflux pump from Stenotrophomonas maltophilia.
Antimicrob Agents Chemother 2000;44:3079–3086.
12. Sanchez MB, Martínez JL. The efflux pump SmeDEF contrib-
utes to trimethoprim-sulfamethoxazole resistance in Stenotro-
phomonas maltophilia. Antimicrob Agents Chemother 2015;59:
4347–4348.
13. Chung HS, Kim K, Hong SS, Hong SG, Lee K et al. The sul1
gene in Stenotrophomonas maltophilia with high-level resis-
tance to trimethoprim/sulfamethoxazole. Ann Lab Med 2015;
35:246–249.
14. Jorgensen JH, Carroll KC, Pfaller MA. Manual of Clinical
Microbiology. Washington, DC: ASM Press; 2015.
15. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of
classifying prognostic comorbidity in longitudinal studies: develop-
ment and validation. J Chronic Dis 1987;40:373–383.
16. Rios-Licea MM, Bosques FJ, Arroliga AC, Galindo-Galindo JO,
Garza-Gonzalez E. Quadruplex real-time quantitative PCR assay
for the detection of pathogens related to late-onset ventilator-
associated pneumonia: a preliminary report. J Microbiol Methods
2010;81:232–234.
17. CLSI. Performance Standards for Antimicrobial Susceptibility
Testing, 26th ed. CLSI supplement M100S. Wayne, PA: Clinical and
Laboratory Standards Institute; 2016.
18. Wang CH, Lin JC, Lin HA, Chang FY, Wang NC et al. Comparisons
between patients with trimethoprim-sulfamethoxazole-susceptible
and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas
maltophilia monomicrobial bacteremia: a 10-year retrospective
study. J Microbiol Immunol Infect 2016;49:378–386.
19. Hotta G, Matsumura Y, Kato K, Nakano S, Yunoki T et al. Risk fac-
tors and outcomes of Stenotrophomonas maltophilia bacteraemia:
a comparison with bacteraemia caused by Pseudomonas aerugi-
nosa and Acinetobacter species. PLoS One 2014;9:e112208.
20. Flores-Treviño S, Gutierrez-Ferman JL, Morfín-Otero R,
Rodríguez-Noriega E, Estrada-Rivadeneyra D et al. Stenotropho-
monas maltophilia in Mexico: antimicrobial resistance, biofilm for-
mation and clonal diversity. J Med Microbiol 2014;63:1524–1530.
21. Cho SY, Kang CI, Kim J, Ha YE, Chung DR et al. Can levofloxacin
be a useful alternative to trimethoprim-sulfamethoxazole for
treating Stenotrophomonas maltophilia bacteremia? Antimicrob
Agents Chemother 2014;58:581–583.
Herrera-Heredia et al., Journal of Medical Microbiology 2017;66:1102–1109
1108
Downloaded from www.microbiologyresearch.org by
IP:  148.234.90.117
On: Mon, 11 Mar 2019 20:04:33
22. Chong SY, Lee K, Chung HS, Hong SG, Suh Y et al. Levofloxacin
Efflux and smeD in clinical isolates of Stenotrophomonas malto-
philia. Microb Drug Resist 2017;23:163–168.
23. Liaw SJ, Lee YL, Hsueh PR. Multidrug resistance in clinical
isolates of Stenotrophomonas maltophilia: roles of integrons,
efflux pumps, phosphoglucomutase (SpgM), and melanin and
biofilm formation. Int J Antimicrob Agents 2010;35:126–130.
24. Perreten V, Boerlin P. A new sulfonamide resistance gene (sul3)
in Escherichia coli is widespread in the pig population of Switzer-
land. Antimicrob Agents Chemother 2003;47:1169–1172.
Herrera-Heredia et al., Journal of Medical Microbiology 2017;66:1102–1109
1109
Five reasons to publish your next article with a Microbiology Society journal
1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around
the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.
Find out more and submit your article at microbiologyresearch.org.
